Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Earlier Anticoagulation Safe in Stroke With AF: ELAN Earlier Anticoagulation Safe in Stroke With AF: ELAN
Patients presenting with ischemic stroke found to have atrial fibrillation can safely start a direct oral anticoagulant much earlier than starting occurs in current practice, a new study suggests.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 24, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
DOACs Safe to Start Soon After Acute Ischemic Stroke
(MedPage Today) -- An earlier start to anticoagulation after an acute ischemic stroke for patients found to have atrial fibrillation appeared safe and possibly improved outcomes, according to the randomized ELAN trial.
Starting a direct oral anticoagulant... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 24, 2023 Category: Cardiology Source Type: news
Disease Burden of Ischemic Stroke Predicted to Continue Increasing
FRIDAY, May 19, 2023 -- The disease burden of ischemic stroke increased from 1990 to 2019 and is predicted to continue increasing, according to a study published online May 17 in Neurology.
Jiahui Fan, from the Shanghai Fourth People ' s Hospital in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 19, 2023 Category: Pharmaceuticals Source Type: news
Stroke Gaining Ground as a Global Killer
FRIDAY, May 19, 2023 -- Worldwide deaths from the most common type of stroke have risen significantly in the past three decades and will increase even more sharply in the years ahead, researchers say.
Ischemic stroke deaths grew from 2 million in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 19, 2023 Category: General Medicine Source Type: news
Roche ’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
Fenebrutinib is an investigational, potent and highly selective oralBruton ’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trialsPhase II study met its primary and secondary endpoints by reducing the total number of new gadolinium-enhancing T1 brain lesions and significantly reducing the total number of new or enlarging T2 brain lesions compared to placeboThe safety profile offenebrutinib was consistent with previous and ongoing clinical trials across more than 2,400 people to dateBasel, 17 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today p...
Source: Roche Media News - May 17, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
Fenebrutinib is an investigational, potent and highly selective oralBruton ’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trialsPhase II study met its primary and secondary endpoints by reducing the total number of new gadolinium-enhancing T1 brain lesions and significantly reducing the total number of new or enlarging T2 brain lesions compared to placeboThe safety profile offenebrutinib was consistent with previous and ongoing clinical trials across more than 2,400 people to dateBasel, 17 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today p...
Source: Roche Investor Update - May 17, 2023 Category: Pharmaceuticals Source Type: news
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). This news follows asundexian's first U.S. FDA Fast Track Designation for the prevention of stroke in patients after a non-cardioembolic ischemic stroke, which was granted in 2022. (Source: World Pharma News)
Source: World Pharma News - May 16, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Statin Use Cuts Five-Year Stroke Risk for Patients With Atrial Fibrillation
MONDAY, May 15, 2023 -- Statin use is associated with a lower risk for incident stroke and transient ischemic attack (TIA) in a duration-dependent manner among patients with atrial fibrillation (AF), according to a study presented at the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 15, 2023 Category: Pharmaceuticals Source Type: news
Acute Ischemic Stroke: Recent Advances in Reperfusion Treatment Acute Ischemic Stroke: Recent Advances in Reperfusion Treatment
Review the latest evidence on reperfusion treatment of acute ischemic stroke, with a focus on endovascular treatment using stent retrievers, aspiration catheters, thrombolytics, and carotid stenting.European Heart Journal (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 10, 2023 Category: Intensive Care Tags: Cardiology Journal Article Source Type: news
Risk for MI, Ischemic Stroke Increased for Younger Adults With Mental Disorders
TUESDAY, May 9, 2023 -- Younger adults with mental disorders have an increased risk for myocardial infarction (MI) and ischemic stroke (IS), according to a study published online April 28 in the European Journal of Preventive Cardiology.
Chan Soon... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 9, 2023 Category: Pharmaceuticals Source Type: news
Mayo Clinic Minute: How vagus nerve stimulation can help some patients improve their recovery after stroke
A vagus nerve stimulation device, approved by the Food and Drug Administration, is being used in rehabilitation to help patients recovering from an ischemic stroke. If a patient is having trouble using their hand or arm after a stroke, this stimulation device helps create new pathways in the brain as the person performs exercises. This can help the person regain function faster than rehabilitation alone. Dr. Jonathon Parker, a Mayo Clinic neurosurgeon, discusses how the… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 2, 2023 Category: Databases & Libraries Source Type: news
What Are the Classifications of Perinatal Stroke?
Discussion
Perinatal stroke occurs in about 1:1000 live births and is a “focal vascular injury from the fetal period to 28 days postnatal age.” Perinatal stroke is the most common cause of hemiparetic cerebral palsy and causes other significant morbidity including cognitive deficits, learning disabilities, motor problems, sensory problems including visual and hearing disorders, epilepsy, and behavioral and psychological problems. Family members are also affected because of the potential anxiety and guilt feelings that having a child with a stroke presents, along with the care that may be needed over the child&#...
Source: PediatricEducation.org - May 1, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Statins Tied to Lower Stroke Risk in Atrial Fibrillation Statins Tied to Lower Stroke Risk in Atrial Fibrillation
Initiation of statins soon after diagnosis of AF is associated with lower risk of ischemic and hemorrhagic strokes; longer-term use is tied to further benefit, a new study shows.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 28, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
' Bony' Stroke: Bone Defects Can Cause Recurrent Stroke'Bony' Stroke: Bone Defects Can Cause Recurrent Stroke
An unusual cause of ischemic stroke -- the presence of structural bone and cartilage anomalies which cause mechanical stress to arteries supplying the brain -- is highlighted in a new study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 20, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
